20/20 Biolabs, Inc. Common Stock

20/20 Biolabs, Inc. Common Stock

AIDX

Get informed when a big investor buys or sells

+ Follow
Market Cap$6.79M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
20/20 Biolabs, Inc. Common Stock20/20 Biolabs, Inc. Common Stock-0.7--429%-0.6
$5.00

Target Price by Analysts

788.1% upside20/20 Biolabs Common Stock Target Price DetailsTarget Price

Share Statistics

Market cap$6.79 Million
Enterprise Value$3.28 Million
Dividend Yield$- (-)
Earnings per Share$-0.6
Beta1.54
Outstanding Shares10,790,722

Return

Return on Equity-428.70%ROE
Return on Assets-113.47%
Return on Invested Capital-132.61%

Valuation & Multiples

P/E Ratio-0.66P/E Ratio
PEG-0.55PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue1.61
Enterprise Value to EBIT-0.69
Enterprise Value to Net Income-1
Total Debt to Enterprise0.32
Debt to Equity0.64Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 17, 2026
EPS Estimate
$-0.12
Average shareholder expectation
Revenue Estimate
$636,000
Average shareholder expectation

Next Earnings Call

Expected Date
September 2, 2026
EPS Estimate
$-0.12
Average shareholder expectation
Revenue Estimate
$636,000
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %3.92%▲ 3.92%
Total Invested$564,802
Investors Holding7▲ 7.00%

ESG Score

No data

About 20/20 Biolabs, Inc. Common Stock

13 employees
CEO: Jonathan Cohen

20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offer...